Autonomix Medical, Inc. has made significant changes following its recent annual meeting, including amendments to its stock plan and the election of new directors. These developments are crucial as they may impact the company's growth strategy and shareholder engagement.

On October 29, 2026, Autonomix Medical held its annual meeting of stockholders, where stockholders approved amendments to the company’s 2023 Stock Plan. This includes an increase in the number of shares of common stock authorized for issuance under the plan by 750,000 shares, bringing the total to 750,353 shares. This amendment is designed to incentivize employees and align their interests with those of the shareholders.

Autonomix Medical, Inc., classified under the SIC code 3841 for Surgical & Medical Instruments & Apparatus, operates primarily in the medical device sector. The company is traded on the Nasdaq under the ticker symbol AMIX. This recent filing, accession number 0001437749-26-034696, highlights the company’s ongoing commitment to growth and adaptation in a competitive industry.

During the annual meeting, a total of 905,610 shares of common stock were voted, representing approximately 46% of the 1,959,938 shares outstanding as of the record date of September 8, 2026. All director nominees were elected, and other matters submitted to a vote were approved by the requisite majority.

Among the proposals put forth was the election of six board nominees, who will serve until the next annual meeting or until their successors are elected. The nominees include Walter V. Klemp and Lori Bisson, among others, each receiving substantial support from shareholders.

Another significant proposal was the ratification of Forvis Mazars, LLP as the company’s independent registered public accounting firm for the year ending March 31, 2027. This proposal received overwhelming approval, with 870,562 votes in favor.

Additionally, shareholders voted on a proposal to amend the company’s certificate of incorporation to grant the Board of Directors authority to affect a reverse stock split of the outstanding shares, with a ratio ranging from 1-for-2 to 1-for-25. This proposal also garnered significant support, indicating shareholder confidence in the board's direction.

As Autonomix Medical continues to evolve, these changes signal a proactive approach to governance and strategic planning. The amendments to the stock plan and the election of new directors may enhance the company’s ability to attract and retain talent, which is vital in the competitive surgical and medical instruments industry.

Looking ahead, Autonomix Medical is expected to file additional reports detailing the outcomes of these proposals and any further developments stemming from the annual meeting. The filing does not specify what happens next, but the company’s commitment to transparency and shareholder engagement remains evident.